Compare DOGZ & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | CNTB |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 128.6M |
| IPO Year | 2017 | 2021 |
| Metric | DOGZ | CNTB |
|---|---|---|
| Price | $11.40 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 796.3K | 87.3K |
| Earning Date | 03-16-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,707,707.00 | $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.47 | N/A |
| 52 Week Low | $6.81 | $0.51 |
| 52 Week High | $38.00 | $3.28 |
| Indicator | DOGZ | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 55.40 |
| Support Level | $11.00 | $2.10 |
| Resistance Level | $12.80 | $2.88 |
| Average True Range (ATR) | 0.55 | 0.23 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 40.87 | 60.44 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.